Blume Capital Management’s Titan Pharmaceuticals TTNP Stock Holding History

Blume Capital Management’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	–	–	238
2019 Q3	$0	Hold	1	–	–	﹤0.01%	235
2019 Q2	$1K	Hold	1	–	–	﹤0.01%	213
2019 Q1	$1K	Hold	1	–	–	﹤0.01%	223
2018 Q4	$1K	Hold	1	–	–	﹤0.01%	220
2018 Q3	$1K	Hold	1	–	–	﹤0.01%	193
2018 Q2	$3K	Hold	1	–	–	﹤0.01%	184
2018 Q1	$2K	Hold	1	–	–	﹤0.01%	210
2017 Q4	$3K	Hold	1	–	–	﹤0.01%	220
2017 Q3	$4K	Hold	1	–	–	﹤0.01%	224
2017 Q2	$5K	Hold	1	–	–	﹤0.01%	184
2017 Q1	$8K	Hold	1	–	–	﹤0.01%	160
2016 Q4	$10K	Hold	1	–	–	0.01%	162
2016 Q3	$15K	Hold	1	–	–	0.01%	140
2016 Q2	$14K	Hold	1	–	–	0.01%	158
2016 Q1	$12K	Hold	1	–	–	0.01%	171
2015 Q4	$11K	Buy	+1	New	+$16.3K	0.01%	181

Other funds holding TTNP

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CWM

Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Blume Capital Management's TTNP Position: Q4 2019 in Review

Blume Capital Management sold out of Titan Pharmaceuticals (TTNP) in Q4 2019, closing a stake of 1 share.

Blume Capital Management first reported a position in TTNP in Q4 2015 and held it in 16 quarters. The position peaked at $15K in Q3 2016. 21 funds tracked by Wall St. Rank hold TTNP as of Q4 2019.

Blume Capital Management reported no remaining Titan Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Blume Capital Management sold 1 Titan Pharmaceuticals share in Q4 2019.
Blume Capital Management first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 16 quarters.
Blume Capital Management's Titan Pharmaceuticals position peaked at $15K in Q3 2016.
21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2019.

Based on Blume Capital Management's 13F filing for Q4 2019, filed 5 Feb 2020.